Skip to content
S3V Vascular Technologies logo
Pre-IPOPublic Limited

S3V Vascular Technologies Unlisted Share Price

S3V Vascular Technologies Limited

Healthcare·Medical Devices

CIN
U33112KA2011PLC059915
ISIN
INE0HGT01012
Incorporated
9 Aug 2011
Registered state
Karnataka

Key valuation

Market cap
₹763 Cr
P/E
10900.0x
Debt / equity
0.1x
Shares outstanding
1,40,00,000

Indicative price

₹545prev ₹545

1M

0.00%

3M

0.00%

6M

+3.81%

Max

+45.33%

Updated 17 Nov 2026, 08:10

Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.

Price history

Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.

+45.33%since 20 Nov 2025High ₹565Low ₹350318 dated snapshots

About S3V Vascular Technologies

S3V Vascular Technologies Limited is a Mysuru-based medical device company founded in 2011. It develops and manufactures minimally invasive devices for cardiovascular, neurovascular and critical care use, aiming to replace imported products.

Its range includes drug-eluting stents, PTCA balloon catheters, aspiration catheters and central venous catheters, and it is expanding in neurovascular devices such as mechanical thrombectomy kits for stroke treatment. R&D and manufacturing are integrated in-house. Vijaya Gopal N. is the co-founder and Managing Director.

S3V reported revenue of ₹14 crore and roughly break-even results in FY2025, with a net worth of ₹141 crore.

Business model

Develops and manufactures minimally invasive cardiovascular medical devices, including stents and catheters.

Key highlights

  • Incorporated in 2011

Financial snapshot

FY2025

Revenue FY2025
₹13.55 Cr
EBITDA
₹1.54 Cr
PAT
₹0.07 Cr
Net worth
₹140.84 Cr
Total debt
₹18.30 Cr
Cash & equivalents
—
Operating cash flow
₹-6.42 Cr
EPS
₹0.05

Management & board

  • BN

    Badari Narayan

    CEO

    25+ years of experience

  • VG

    Vijaya Gopal Nagaradagadde

    Managing Director, Co-founder

    15+ years of experience

  • VS

    Vishnu Shreyas Nagaradagadde

    CFO

  • AM

    Anuj Mehta

    Company Secretary

Reported financials · FY2024–FY2025

Figures in ₹ crore unless stated.

Revenue CAGR -9.2%
ParticularsFY2024FY2025YoYCAGR
Profit & loss
Revenue from operationsYoY -9.2%CAGR -9.2%1514-9.2%-9.2%
Other incomeYoY +947.8%CAGR +947.8%02+947.8%+947.8%
Total expensesYoY -8.8%CAGR -8.8%1817-8.8%-8.8%
EBITDA-12——
Depreciation & amortisationYoY -33.3%CAGR -33.3%21-33.3%-33.3%
EBIT-30——
Finance cost00——
Profit before tax-30——
Tax expense-0-0——
Profit after tax-30——
Earnings per share₹-2.29₹0.05——
Balance sheet
Net worthYoY 0.0%CAGR 0.0%1411410.0%0.0%
Total debtYoY -27.7%CAGR -27.7%2518-27.7%-27.7%
Current liabilitiesYoY -9.9%CAGR -9.9%2624-9.9%-9.9%
Current assetsYoY -34.3%CAGR -34.3%11475-34.3%-34.3%
Total assetsYoY -4.3%CAGR -4.3%178170-4.3%-4.3%
Cash flow
Operating activities-7-6——
Investing activities-30-31——
Financing activitiesYoY -110.6%CAGR —93-10-110.6%—
Free cash flow-38-38——
Net change in cashYoY -186.1%CAGR —55-47-186.1%—

YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.

Margins, returns, liquidity, leverage and every other ratio from these figures: see Ratios

Revenue, EBITDA and PAT

₹ crore. A year with no reported figure is left out rather than drawn as zero.

-3161015FY2024 · Revenue: 15FY2024 · EBITDA: -1FY2024 · PAT: -3FY2024FY2025 · Revenue: 14FY2025 · EBITDA: 2FY2025 · PAT: 0FY2025
-3161015FY2024 · Revenue: 15FY2024 · EBITDA: -1FY2024 · PAT: -3FY2024FY2025 · Revenue: 14FY2025 · EBITDA: 2FY2025 · PAT: 0FY2025
  • Revenue
  • EBITDA
  • PAT

Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.

Valuation multiples

What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹545 indicative price.

Market cap
₹763 Cr
Enterprise value
₹781 Cr
Price / earnings (P/E)
10900.00x
Price / book (P/B)
5.42x
Price / sales (P/S)
56.31x
EV / EBITDA
507.34x
EV / EBIT
4883.13x
EV / sales
57.66x
Earnings yield
0.0%
Free cash flow yield
-4.9%
How these are worked out
Market cap
Indicative price × shares outstanding
Enterprise value
Market cap + debt − cash
Price / earnings (P/E)
Market cap ÷ PAT (profitable years only)
Price / book (P/B)
Market cap ÷ net worth
Price / sales (P/S)
Market cap ÷ revenue from operations
EV / EBITDA
Enterprise value ÷ EBITDA
EV / EBIT
Enterprise value ÷ (EBITDA − depreciation)
EV / sales
Enterprise value ÷ revenue from operations
Earnings yield
PAT ÷ market cap
Free cash flow yield
(Operating cash flow − capex) ÷ market cap

Shareholding pattern

Latest disclosed. The source does not state a date.

Largest holder: N G Badari Narayan 16.76%

16.8%8.4%45.9%

IPO / listing status

Pre-IPONot yet announced

The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.

Research & news

Information currently unavailable

Nothing has been published on S3V Vascular Technologies yet. Research, news and articles tagged with it will appear here when they are.

Browse all research

Documents

Private documents are shown locked and are released to verified clients on request.

DocumentTypeFY / dateAccess
Annual Report FY 2023-24Annual report · FY 2023-24 · 570 KB570 KBAnnual reportFY 2023-24ViewDownload

S3V Vascular Technologies unlisted shares: FAQs

What is the S3V Vascular Technologies unlisted share price today?

The indicative price of S3V Vascular Technologies Limited shares is ₹545 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.

How can I buy S3V Vascular Technologies unlisted shares?

Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.

How can I sell S3V Vascular Technologies shares?

Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.

Is S3V Vascular Technologies planning an IPO?

S3V Vascular Technologies Limited is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.

What are S3V Vascular Technologies's revenue and profit?

In FY25, S3V Vascular Technologies Limited reported revenue of ₹14 Cr and a profit of ₹0 Cr, with a net worth of ₹141 Cr. The Financials section has the full statements for every year we hold.

Is it legal to buy unlisted shares in India?

Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.

Is there a lock-in on S3V Vascular Technologies shares after the IPO?

SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.

How are gains on S3V Vascular Technologies unlisted shares taxed?

Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.